Rupal S Bhatt

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. pmc Molecular pathways: can activin-like kinase pathway inhibition enhance the limited efficacy of VEGF inhibitors?
    Rupal S Bhatt
    Authors Affiliations Division of Hematology Oncology and Cancer Biology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts and Departments of Oncology and Medicine, Georgetown Lombardi Comprehensive Cancer Center, Washington, District of Columbia
    Clin Cancer Res 20:2838-45. 2014
  2. pmc Cox-2 inhibition enhances the activity of sunitinib in human renal cell carcinoma xenografts
    X Wang
    Department of Radiology, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue, Boston, MA 02215, USA
    Br J Cancer 108:319-26. 2013
  3. ncbi request reprint Biomarkers for monitoring antiangiogenic therapy
    Rupal S Bhatt
    Division of Hematology Oncology, Department of Medicine, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA 02215, USA
    Clin Cancer Res 13:777s-780s. 2007
  4. pmc A phase 2 pilot trial of low-dose, continuous infusion, or "metronomic" paclitaxel and oral celecoxib in patients with metastatic melanoma
    Rupal S Bhatt
    Division of Hematology and Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
    Cancer 116:1751-6. 2010
  5. pmc Renal cancer resistance to antiangiogenic therapy is delayed by restoration of angiostatic signaling
    Rupal S Bhatt
    Division of Hematology Oncology and Cancer Biology, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
    Mol Cancer Ther 9:2793-802. 2010
  6. pmc Increased mobilisation of circulating endothelial progenitors in von Hippel-Lindau disease and renal cell carcinoma
    R S Bhatt
    Division of Hematology Oncology and Cancer Biology, Beth Israel Deaconess Medical Center, 375 Longwood Avenue, MASCO 426, Boston, MA 02215, USA
    Br J Cancer 105:112-7. 2011
  7. pmc High dose intermittent sorafenib shows improved efficacy over conventional continuous dose in renal cell carcinoma
    Xiaoen Wang
    Department of Radiology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
    J Transl Med 9:220. 2011
  8. ncbi request reprint Angiopoietin 2 is a potential mediator of high-dose interleukin 2-induced vascular leak
    Diana C Gallagher
    Division of Pulmonary and Critical Care, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
    Clin Cancer Res 13:2115-20. 2007
  9. pmc Resistance of renal cell carcinoma to sorafenib is mediated by potentially reversible gene expression
    Liang Zhang
    Division of Hematology Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States of America
    PLoS ONE 6:e19144. 2011
  10. pmc Inhibition of ALK1 signaling with dalantercept combined with VEGFR TKI leads to tumor stasis in renal cell carcinoma
    Xiaoen Wang
    Department of Radiology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
    Oncotarget 7:41857-41869. 2016

Collaborators

Detail Information

Publications19

  1. pmc Molecular pathways: can activin-like kinase pathway inhibition enhance the limited efficacy of VEGF inhibitors?
    Rupal S Bhatt
    Authors Affiliations Division of Hematology Oncology and Cancer Biology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts and Departments of Oncology and Medicine, Georgetown Lombardi Comprehensive Cancer Center, Washington, District of Columbia
    Clin Cancer Res 20:2838-45. 2014
    ..Targeting of alternate angiogenic pathways, particularly in combination with VEGF pathway blockade, holds the promise of optimally inhibiting angiogenically driven tumor progression. Clin Cancer Res; 20(11); 2838-45. ©2014 AACR. ..
  2. pmc Cox-2 inhibition enhances the activity of sunitinib in human renal cell carcinoma xenografts
    X Wang
    Department of Radiology, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue, Boston, MA 02215, USA
    Br J Cancer 108:319-26. 2013
    ..As COX-2 is a known mediator of tumour growth, we explored the potential benefit of COX-2 inhibition in combination with VEGFR inhibition in attempts at delaying tumour progression on Su...
  3. ncbi request reprint Biomarkers for monitoring antiangiogenic therapy
    Rupal S Bhatt
    Division of Hematology Oncology, Department of Medicine, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA 02215, USA
    Clin Cancer Res 13:777s-780s. 2007
    ..Surrogate markers of angiogenesis could help with selecting patients for therapy, determining optimal dosing of therapy, deciding whether to change therapy, and assessing appropriate salvage therapy...
  4. pmc A phase 2 pilot trial of low-dose, continuous infusion, or "metronomic" paclitaxel and oral celecoxib in patients with metastatic melanoma
    Rupal S Bhatt
    Division of Hematology and Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
    Cancer 116:1751-6. 2010
    ..Angiogenesis, which is the growth of new blood vessels, is necessary for tumor growth and progression. Thus, the authors tested the safety and efficacy of a low dose of paclitaxel and celecoxib in patients with MM...
  5. pmc Renal cancer resistance to antiangiogenic therapy is delayed by restoration of angiostatic signaling
    Rupal S Bhatt
    Division of Hematology Oncology and Cancer Biology, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
    Mol Cancer Ther 9:2793-802. 2010
    ....
  6. pmc Increased mobilisation of circulating endothelial progenitors in von Hippel-Lindau disease and renal cell carcinoma
    R S Bhatt
    Division of Hematology Oncology and Cancer Biology, Beth Israel Deaconess Medical Center, 375 Longwood Avenue, MASCO 426, Boston, MA 02215, USA
    Br J Cancer 105:112-7. 2011
    ..Because of the highly angiogenic phenotype of renal cell carcinoma (RCC), we sought to assess the potential of CECs as a marker of RCC in patients with von Hippel-Lindau (VHL) disease and those with sporadic RCC...
  7. pmc High dose intermittent sorafenib shows improved efficacy over conventional continuous dose in renal cell carcinoma
    Xiaoen Wang
    Department of Radiology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
    J Transl Med 9:220. 2011
    ..However, resistance to therapy develops at a median of 5 months. In an effort to increase efficacy, we studied the effects of increased sorafenib dose and intermittent scheduling in a murine RCC xenograft model...
  8. ncbi request reprint Angiopoietin 2 is a potential mediator of high-dose interleukin 2-induced vascular leak
    Diana C Gallagher
    Division of Pulmonary and Critical Care, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
    Clin Cancer Res 13:2115-20. 2007
    ..However, a major toxicity is vascular leak syndrome (VLS). We previously reported elevated serum angiopoietin 2 (Ang2) in septic patients with vascular leak and hypothesized that Ang2 might also contribute to HDIL2 VLS...
  9. pmc Resistance of renal cell carcinoma to sorafenib is mediated by potentially reversible gene expression
    Liang Zhang
    Division of Hematology Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States of America
    PLoS ONE 6:e19144. 2011
    ..We examined whether resistance occurs at least in part via reversible, physiologic changes in the tumor, or results solely from stable genetic changes in resistant tumor cells...
  10. pmc Inhibition of ALK1 signaling with dalantercept combined with VEGFR TKI leads to tumor stasis in renal cell carcinoma
    Xiaoen Wang
    Department of Radiology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
    Oncotarget 7:41857-41869. 2016
    ..At the molecular level, combination therapy leads to downregulation of Notch signaling...
  11. pmc Selective spectroscopic imaging of hyperpolarized pyruvate and its metabolites using a single-echo variable phase advance method in balanced SSFP
    Gopal Varma
    Division of MR Research, Department of Radiology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
    Magn Reson Med 76:1102-15. 2016
    ..This work describes a method based on use of a variable RF phase advance to acquire spatial and spectral data in a time-efficient manner for hyperpolarized 13C MRI...
  12. doi request reprint Phase 2 Study of Bevacizumab and Temsirolimus After VEGFR TKI in Metastatic Renal Cell Carcinoma
    Kathleen M Mahoney
    Division of Hematology Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA
    Clin Genitourin Cancer 14:304-313.e6. 2016
    ....
  13. pmc Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell Carcinoma
    Marcella Callea
    Department of Pathology, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts
    Cancer Immunol Res 3:1158-64. 2015
    ..Notably, because PD-L1 expression was mostly detected in high nuclear grade areas, to avoid false-negative results, these areas should be specifically selected for assessment...
  14. pmc Hypoxia-inducible factor-2alpha: effect on radiation sensitivity and differential regulation by an mTOR inhibitor
    Rupal S Bhatt
    Division of Cancer Biology, Beth Israel Deaconess Medical Center, Boston, MA, USA
    BJU Int 102:358-63. 2008
    ....
  15. pmc Phase 2 study of neoadjuvant docetaxel plus bevacizumab in patients with high-risk localized prostate cancer: a Prostate Cancer Clinical Trials Consortium trial
    Robert W Ross
    Dana Farber Cancer Institute, Boston, Massachusetts, USA
    Cancer 118:4777-84. 2012
    ..Treatment of high-risk localized prostate cancer remains inadequate. The authors performed a phase 2 multicenter trial of neoadjuvant docetaxel plus bevacizumab before radical prostatectomy...
  16. pmc Anti-S1P Antibody as a Novel Therapeutic Strategy for VEGFR TKI-Resistant Renal Cancer
    Liang Zhang
    Division of Hematology Oncology and Cancer Biology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts
    Clin Cancer Res 21:1925-34. 2015
    ..However, resistance to treatment is inevitable. Identification of novel targets could lead to better treatment for patients with TKI-naïve or -resistant RCC...
  17. doi request reprint The challenge of herbal therapies for prostate cancer
    Rupal S Bhatt
    Cancer Biology and Division of Hematology Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
    Clin Cancer Res 14:7581-2. 2008
    ..Identification of the biological effects of herbal remedies such as silibinin is critical for their development as anticancer treatments...
  18. pmc Angiotensin system inhibitors and survival outcomes in patients with metastatic renal cell carcinoma
    Rana R McKay
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts
    Clin Cancer Res 21:2471-9. 2015
    ..The purpose of this study was to evaluate the impact of angiotensin system inhibitors (ASI) on outcomes in metastatic renal cell carcinoma (mRCC) patients treated in the targeted therapy era...
  19. pmc The high-dose aldesleukin "select" trial: a trial to prospectively validate predictive models of response to treatment in patients with metastatic renal cell carcinoma
    David F McDermott
    Beth Israel Deaconess Medical Center, Dana Farber Harvard Cancer Center, Boston, Massachusetts
    Clin Cancer Res 21:561-8. 2015
    ..Retrospective studies suggested that clinical and pathologic features could predict for benefit. The Cytokine Working Group conducted this prospective trial to validate proposed predictive markers of response to HD IL2...